This move is archived. Current quotes and coverage live on the stock page.
Follow XRTX
XORTX Therapeutics Inc has seen a remarkable surge in its stock price, gaining over 9% in just one trading day.
In a notable turn of events, XORTX Therapeutics Inc (XRTX.V) has experienced a significant price increase of 9.21%, closing at CA$3.20. This surge comes amidst corporate updates and strategic decisions that could shape the company's future.
Investor takeaway: For investors, XORTX's recent performance may signal growing confidence in its strategic direction and potential for future growth.
XORTX Therapeutics Inc
XRTX.V
XRTX.V
XORTX Therapeutics Inc
WealthAwesomeMarket cap
$5.79M
52W high
$9.85
52W low
$2.42
1W change
+0.00%
Beta
0.08
Analyst Price Targets
Based on analyst covering XRTX · as of Sep 17, 2026
Wall Street analysts forecast XRTX stock price to rise 8704.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$81.00
+8704.3% Upside
Current Price
C$0.92
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on XRTX's historical volatility
30-Day Vol
114.6%
Annualized
90-Day Vol
129.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.39 | C$2.28 – C$5.03 |
| 60 trading days | C$3.59 | C$2.05 – C$6.28 |
| 90 trading days | C$3.81 | C$1.92 – C$7.56 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
XORTX Therapeutics Inc gains 9.21% in one day
With a market cap of CA$5.5 million, XORTX's stock price increase reflects a growing interest among investors despite its recent challenges.
Bull case
The recent appointment of Mika Grasso as Co-CEO could bring fresh leadership and vision to XORTX. Investors are optimistic that this new leadership will drive innovation and improve operations.
Bear case
Despite the positive movement, the lack of substantial recent news and the company's voluntary delisting from the TSX Venture Exchange may raise concerns about its long-term viability.
Recent Performance Highlights
XORTX Therapeutics Inc's stock price jumped by 9.21% in the last trading session, closing at CA$3.20. This increase is significant for a company with a market cap of CA$5.5 million, indicating a potential shift in investor sentiment.
Leadership Changes and Strategic Direction
The recent appointment of Mika Grasso as Co-CEO could be a pivotal moment for XORTX. Investors are hopeful that new leadership will bring innovative strategies and enhance the company's operational efficiency, especially as it navigates its voluntary delisting from the TSX Venture Exchange.
Market Considerations
While the stock's performance is encouraging, investors should remain cautious. The absence of significant news and the company's recent decisions may imply underlying challenges. Monitoring future developments will be crucial for understanding XORTX's trajectory.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
